Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

Colomer, Ramon; Aranda-Lopez, Ignacio; Albanell Mestres, Joan; García-Caballero, Tomás; Ciruelos, Eva; Lopez-García,  M. A.; Cortés, Javier; Rojo, Federico; Martín, M.; Palacios-Calvo, J.

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Colomer, Ramonca
dc.contributor.author Aranda-Lopez, Ignacioca
dc.contributor.author Albanell Mestres, Joanca
dc.contributor.author García-Caballero, Tomásca
dc.contributor.author Ciruelos, Evaca
dc.contributor.author Lopez-García, M. A.ca
dc.contributor.author Cortés, Javierca
dc.contributor.author Rojo, Federicoca
dc.contributor.author Martín, M.ca
dc.contributor.author Palacios-Calvo, J.ca
dc.date.accessioned 2018-10-24T07:40:40Z
dc.date.available 2018-10-24T07:40:40Z
dc.date.issued 2018
dc.description.abstract This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy. One of the four available genetic prognostic platforms (MammaPrint®, Oncotype DX®, Prosigna® or EndoPredict®) may be used in node-negative ER-positive patients to establish a prognostic category and decide with the patient whether adjuvant treatment may be limited to hormonal therapy. Newer technologies including next-generation sequencing, liquid biopsy, tumour-infiltrating lymphocytes or PD-1 determination are at this point investigational.
dc.format.mimetype application/pdf
dc.identifier.citation Colomer R, Aranda-López I, Albanell J, García-Caballero T, Ciruelos E, López-García MA et al. Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2018 Jul;20(7):815-26. DOI: 10.1007/s12094-017-1800-5
dc.identifier.doi http://dx.doi.org/10.1007/s12094-017-1800-5
dc.identifier.issn 1699-048X
dc.identifier.uri http://hdl.handle.net/10230/35642
dc.language.iso eng
dc.publisher SpringerOpenca
dc.relation.ispartof Clinical and Translational Oncology. 2018 Jul;20(7):815-26
dc.rights Copyright © The Author(s) 2017. Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.subject.keyword Breast neoplasm
dc.subject.keyword Diagnostic
dc.subject.keyword Gene expression profiling
dc.subject.keyword Prognostic
dc.subject.keyword Therapy predictive
dc.subject.other Marcadors bioquímics
dc.subject.other Mama -- Càncer
dc.title Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathologyca
dc.type info:eu-repo/semantics/article
dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)
Articles (Departament de Medicina i Ciències de la Vida)